Authors: Wimalawansa SJ. PMID: 35889955 PMCID: PMC9319502 DOI: 10.3390/nu14142997 Abstract Vitamin D deficiency is a global public health problem, a pandemic that commonly affects the elderly and those with comorbidities such as obesity, diabetes, hypertension, respiratory disorders, recurrent infections, immune deficiency, and malignancies, as well as ethnic minorities living in temperate countries. The same groups [...]

Authors: Hazan S, Dave S, Gunaratne AW, Dolai S, Clancy RL, McCullough PA et al. PMID: 35135310 PMCID: PMC8826831 DOI: 10.2217/fmb-2022-0014 Abstract Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic [...]

Authors: Izquierdo JL, Soriano JB, Gonzalez Y, Lumbreras S PMID: 35084258 PMCID: PMC8795755 DOI: 10.1177/00368504221074574 Abstract Infection by SARS-CoV-2 causing coronavirus disease 2019 (COVID-19) can be associated with serious and life-threatening conditions, including acute respiratory distress syndrome (ARDS). Severity and mortality have been related to a cytokine storm, an imbalance of oxidative stress, and a [...]

Authors: Kumar P, Osahon O, Vides DB, Hanania N, Minard CG PMID: 35052554 PMCID: PMC8773164 DOI: 10.3390/antiox11010050 Abstract Humanity is battling a respiratory pandemic pneumonia named COVID-19 which has resulted in millions of hospitalizations and deaths. COVID-19 exacerbations occur in waves that continually challenge healthcare systems globally. Therefore, there is an urgent need to understand [...]

Authors: Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Lopez-Miranda J PMID: 34862422 PMCID: PMC8642445 DOI: 10.1038/s41598-021-02701-5 Abstract COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival [...]

Authors: Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Likic R PMID: 34719789 PMCID: PMC8653355 DOI: 10.1111/bcp.15126 Abstract Aims: Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in three trials. The aim of this [...]

Authors: Kennedy RF PMID: Abstract Over 1,000,000 copies sold despite censorship, boycotts from bookstores and libraries, and hit pieces against the author. Pharma-funded mainstream media has convinced millions of Americans that Dr. Anthony Fauci is a hero. Hands down, he is anything but. As director of the National Institute of Allergy and Infectious Diseases [...]

Authors: Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Sirota M PMID: 34779847 PMCID: PMC8593759 DOI: 10.1001/jamanetworkopen.2021.33090 Abstract Importance: Antidepressant use may be associated with reduced levels of several proinflammatory cytokines suggested to be involved with the development of severe COVID-19. An association between the use of selective serotonin reuptake inhibitors (SSRIs)-specifically fluoxetine [...]

Authors: Reis G, Moreira-Silva EA, Silva DC, Thabane L, Guyatt GH, Mills EJ PMID: 34717820 PMCID: PMC8550952 DOI: 10.1016/S2214-109X(21)00448-4 Abstract Background: Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation [...]

Authors: Peterson DJ. PMID: Abstract Keywords: Source: https://ago.nebraska.gov/sites/ago.nebraska.gov/files/docs/opinions/21-017_0.pdf Archive: https://archive.is/EoVhB